Location: Virtual Live Stream
Hoot founder and CEO Bob Migliani sits down with Jason Grossman, a 25+ year pharma commercial and patient services leader, to unpack the fast-moving shift to the direct-to-patient model. They discuss what’s driving the change (specialty/rare disease growth, cost pressure, and rising patient confusion), what happens after diagnosis when time with HCPs is limited, and why education + adherence support will matter as much as access. Expect a candid look at what patient services, hub, and brand leaders should prioritize in 2026.
